user

Tepotinib in non-small cell lung cancer (NSCLC) with MET-exon 14 skipping mutations (METex14+) and MET amplification (METamp); A phase II trial in progress

被引：0
|
作者：
Paik, P. [1 ]
Sakai, H. [2 ]
Bruns, R. [3 ]
Scheele, J. [4 ]
Straub, J. [5 ]
Felip, E. [6 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[2] Saitama Canc Ctr, Dept Thorac Oncol, Saitama, Japan
[3] Merck KGaA, Biostat, Darmstadt, Germany
[4] Merck KGaA, Clin Oncol, Darmstadt, Germany
[5] Merck KGaA, Global Early Dev, Darmstadt, Germany
[6] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
546TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tepotinib in Non-Small Cell Lung Cancer with MET Exon 14-Skipping Mutations or MET Amplification: a Phase 2 Trial in Progress
    Paik, P.
    Sakai, H.
    Bruns, R.
    Scheele, J.
    Straub, J.
    Felip, E.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1046 - S1046
  • [2] Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)
    Reinmuth, N.
    Popat, S.
    Paz-Ares, L.
    Knowles, E.
    Hatswell, A.
    McLean, T.
    Adrian, S.
    Gaumond, B.
    Vioix, H.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2021, 32 : S985 - S986
  • [3] Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC
    Scherz, A.
    Felip, E.
    Garassino, M.
    Sakai, H.
    Le, X.
    Veillon, R.
    Smit, E.
    Mazieres, J.
    Cortot, A.
    Raskin, J.
    Viteri, S.
    Iams, W. Thomas
    Kim, H. R.
    Yang, J. -J.
    Stroh, C.
    Otto, G.
    Bruns, R.
    Paik, P.
    SWISS MEDICAL WEEKLY, 2021, 151 : 36 - 36
  • [4] Updated molecular analysis of MET exon 14 skipping mutations (METex14) in non-small cell lung cancer (NSCLC)
    Marks, Jennifer Aline
    Gandhi, Nishant
    Halmos, Balazs
    Ramalingam, Suresh S.
    Bazhenova, Lyudmila
    Marmarelis, Melina Elpi
    Xiu, Joanne
    Walker, Phillip
    Oberley, Matthew James
    Ma, Patrick C.
    Liu, Stephen V.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] MET exon 14 skipping mutations in advanced non-small cell lung cancer (NSCLC) are not associated with MET amplification and overexpression
    Gimenez-Capitan, Ana
    Teixido, Cristina
    Aguado, Cristina
    Rodriguez, Sonia
    Bertran-Alamillo, Jordi
    Castellvi, Josep
    Yeste, Zaira
    Perez, Ana
    Rosell, Rafael
    Molina-Vila, Miguel Angel
    CANCER RESEARCH, 2017, 77
  • [6] Tepotinib in patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon 14-skipping mutations: Phase II trial.
    Felip, Enriqueta
    Horn, Leora
    Patel, Jyoti D.
    Sakai, Hiroshi
    Scheele, Juergen
    Bruns, Rolf
    Paik, Paul K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Tepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: Phase II data
    Sakai, H.
    Felip, E.
    Cortot, A. B.
    Veillon, R.
    Griesinger, F.
    Patel, J.
    Horn, L.
    Mazieres, J.
    De Castro Carpeno, J.
    Morise, M.
    Sakamoto, T.
    Bruns, R.
    Scheele, J.
    Straub, J.
    Paik, P.
    ANNALS OF ONCOLOGY, 2018, 29 : 152 - 152
  • [8] Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
    Paik, Paul K.
    Felip, Enriqueta
    Veillon, Remi
    Sakai, Hiroshi
    Cortot, Alexis B.
    Garassino, Marina C.
    Mazieres, Julien
    Viteri, Santiago
    Senellart, Helene
    Van Meerbeeck, Jan
    Raskin, Jo
    Reinmuth, Niels
    Conte, Pierfranco
    Kowalski, Dariusz
    Cho, Byoung Chul
    Patel, Jyoti D.
    Horn, Leora
    Griesinger, Frank
    Han, Ji-Youn
    Kim, Young-Chul
    Chang, Gee-Chen
    Tsai, Chen-Liang
    Yang, James C. -H.
    Chen, Yuh-Min
    Smit, Egbert F.
    van der Wekken, Anthonie J.
    Kato, Terufumi
    Juraeva, Dilafruz
    Stroh, Christopher
    Bruns, Rolf
    Straub, Josef
    Johne, Andreas
    Scheele, Juergen
    Heymach, John V.
    Le, Xiuning
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (10): : 931 - 943
  • [9] US health utility in advanced non-small cell lung cancer (NSCLC) patients harboring MET exon 14 (METex14) skipping mutations treated with tepotinib
    Paik, Paul K.
    Yang, Mo
    Knowles, Emma
    Hatswell, Anthony
    Vioix, Helene
    Liu, Frank Xiaoqing
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [10] Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+).
    Lu, Shun
    Fang, Jian
    Li, Xingya
    Cao, Lejie
    Zhou, Jianying
    Guo, Qisen
    Liang, Zongan
    Cheng, Ying
    Jiang, Liyan
    Yang, Nong
    Han, Zhigang
    Shi, Jianhua
    Chen, Yuan
    Xu, Hua
    Zhang, Helong
    Zhang, Di
    Li, Jing
    Wang, Linfang
    Ren, Yongxin
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345